2023 annual financial data
Estrella Immunopharma 2023 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -7,310,098 USD and net income was -7,311,723 USD.
Operating cash flow was -16,068,306 USD.
Get free Estrella Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -7,310,098 USD
- Net income
- -7,311,723 USD
- Operating cash flow
- -16,068,306 USD